Field & Main Bank Buys New Holdings in Thermo Fisher Scientific Inc. $TMO

Field & Main Bank purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,714 shares of the medical research company’s stock, valued at approximately $859,000.

A number of other hedge funds also recently made changes to their positions in the business. Lombard Odier Asset Management Europe Ltd acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $18,456,000. Archer Investment Corp acquired a new position in Thermo Fisher Scientific in the second quarter worth about $490,000. Kingsview Wealth Management LLC acquired a new stake in Thermo Fisher Scientific during the second quarter valued at approximately $3,881,000. Beacon Pointe Advisors LLC acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth approximately $18,906,000. Finally, Ratan Capital Management LP bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $777,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 11,440 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the transaction, the vice president owned 14,784 shares in the company, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Joseph R. Holmes sold 420 shares of the business’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the transaction, the chief accounting officer directly owned 2,966 shares of the company’s stock, valued at $1,734,546.46. This trade represents a 12.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 73,768 shares of company stock valued at $44,122,820 in the last three months. 0.33% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have weighed in on TMO. Stifel Nicolaus set a $650.00 price target on Thermo Fisher Scientific in a research report on Wednesday, August 5th. KeyCorp restated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. HSBC cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and dropped their target price for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Sanford C. Bernstein assumed coverage on shares of Thermo Fisher Scientific in a research report on Friday, June 26th. They issued a “market perform” rating and a $520.00 price target on the stock. Finally, Barclays raised their price objective on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $619.41.

Thermo Fisher Scientific Stock Down 1.4%

NYSE:TMO opened at $621.87 on Friday. The company has a market cap of $229.94 billion, a price-to-earnings ratio of 33.45, a P/E/G ratio of 2.57 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The stock’s fifty day moving average price is $558.64 and its two-hundred day moving average price is $512.08. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $647.00.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm’s quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.